Transforming Clinical Trials: AI Solutions by LabConnect and OmniScience
Revolutionizing Clinical Trials with AI Technology
Together we're unlocking the true potential of clinical trial lab data, bringing faster insights, smarter decisions, and better outcomes.
LabConnect, a leader in central laboratory services, has announced an exciting partnership with OmniScience, the creator of Vivo, a cutting-edge AI control tower designed specifically for clinical trials. This collaboration aims to introduce the first AI-driven solution that empowers sponsors with intelligent, real-time insights extracted from clinical trial lab data.
Enhancing Decision-Making in Clinical Trials
Clinical trial lab data is frequently fragmented and complex, leading to slow decision-making and increased risk. However, by amalgamating LabConnect's proficiency in central lab testing with OmniScience's innovative Vivo platform, trial sponsors can now integrate disparate lab data sources, enhance oversight, and detect risk signals that not only accelerate trial timelines but also elevate overall outcomes.
Vivo: A Revolutionary AI-Native Platform
Vivo stands out as a specialized AI-driven clinical trial intelligence platform that changes the way teams interact with data throughout the clinical development lifecycle. By uniting various data sources and providing real-time insights, Vivo serves as a control tower that equips clinical, operational, safety, and data science teams with the clarity needed to respond promptly and confidently. The specific version, Vivo-Lab, tailors this intelligence for laboratory data, improving workflows by identifying critical trends and anomalies as they occur, ultimately facilitating a proactive approach in managing complex clinical research.
Real-Time Actionable Intelligence
Angela Holmes, CEO and Co-Founder of OmniScience, emphasized the goal of the partnership, stating, "Our mission at OmniScience is to help trial teams see and act faster. By collaborating with LabConnect, we aim to transform lab data into real-time actionable intelligence that sponsors can rely on." Wes Wheeler, CEO of LabConnect, echoed this sentiment, expressing the importance of integrating OmniScience's transformative AI to transition lab results from static reports to dynamic, actionable intelligence. This partnership empowers clinical operations teams with the agility and precision necessary for informed decision-making, improving trial efficiency, and expediting the delivery of therapies to patients.
Innovation at the Forefront
The strategic alliance between LabConnect and OmniScience highlights both organizations' dedication to innovation within the clinical development space. By combining LabConnect's technology-driven lab operations with OmniScience's AI-enabled trial intelligence approach, they aim to set new standards for clinical trials.
About LabConnect
LabConnect, LLC is renowned for offering Central Laboratory Services, FSP and Scientific Consulting, alongside Data Integration and Transformation Services. It specializes in managing analytically and logistically challenging studies, including those in immuno-oncology, cell and gene therapies, and rare and orphan disorders. The unique blend of cutting-edge technology, access to both emerging and established markets, and extensive expertise in specialized testing makes LabConnect a dependable partner for drug development companies seeking comprehensive lab services.
About OmniScience
OmniScience is a pioneering AI company dedicated to transforming clinical development through Vivo, the first agentic AI control tower built specifically for clinical trials. With a team of PhD-trained clinical data scientists, OmniScience is committed to unifying disjointed trial data, applying intelligent automation, and providing real-time, easily interpreted insights that empower sponsors to minimize costs, reduce timelines, and enhance trial success rates. Recognized by prestigious programs, OmniScience is at the forefront of clinical trial intelligence, aiming to accelerate the process of delivering transformative treatments to patients.
Frequently Asked Questions
What are the benefits of the LabConnect and OmniScience partnership?
The partnership aims to transform clinical trial processes by providing real-time insights and enhancing decision-making through AI-driven solutions.
How does Vivo work within clinical trials?
Vivo serves as a control tower, integrating various data sources and delivering real-time insights to support trial teams in making informed decisions swiftly.
What types of studies does LabConnect specialize in?
LabConnect focuses on complex studies such as immuno-oncology, cell and gene therapies, and rare diseases, providing full laboratory services.
Who leads OmniScience and what is their mission?
Angela Holmes is the CEO and Co-Founder of OmniScience, whose mission is to empower trial teams with faster visibility and actionable intelligence from lab data.
What distinguishes OmniScience's approach to clinical trials?
OmniScience's AI-native approach allows for intelligent automation and real-time insights, aiming to reduce costs and enhance the likelihood of trial success.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
